Hirtle Callaghan & Co LLC Acquires New Position in Danaher Corporation (NYSE:DHR)

Key Points

• Hirtle Callaghan & Co LLC made a new investment of approximately $1.08 million in Danaher Corporation by acquiring 5,259 shares in the first quarter.
• Several hedge funds have significantly increased their positions in Danaher, with GAMMA Investing LLC increasing its stake by 24,958.2%, bringing its total to 1.87 million shares worth $383.5 million.
• Analysts have mixed views on Danaher, with target prices ranging from $205.00 to $275.00, leading to a consensus rating of "Moderate Buy."

Hirtle Callaghan & Co LLC acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,259 shares of the conglomerate's stock, valued at approximately $1,078,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. lifted its holdings in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter valued at $27,000. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in Danaher during the first quarter valued at $31,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 1.1%

Shares of DHR stock traded up $2.21 during trading hours on Friday, hitting $200.70. The company had a trading volume of 2,963,091 shares, compared to its average volume of 4,823,699. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market capitalization of $143.71 billion, a PE ratio of 42.70, a price-to-earnings-growth ratio of 2.80 and a beta of 0.73. The company's fifty day moving average is $198.46 and its 200 day moving average is $200.94. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on DHR. Bank of America decreased their price objective on shares of Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Leerink Partners raised their price target on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 23rd. Robert W. Baird raised their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Argus decreased their price target on shares of Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Finally, UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $247.61.

Insider Transactions at Danaher

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.